Estrella Immunopharma highlights Artemis T-cell therapy data selected for ASH 2026
ESLA•Estrella Immunopharma said its Artemis T-cell therapy data selected for ASH 2026 demonstrate deep, durable leukemia responses and superior extramedullary disease clearance versus conventional CAR-T in preclinical models.
1. Preclinical findings
Estrella Immunopharma highlighted data on its Artemis T-cell therapy selected for ASH 2026, saying the preclinical models demonstrated deep and durable leukemia responses and superior extramedullary disease clearance versus conventional CAR-T.




